1-(2,2-diethoxyethoxy)-3-butoxybenzene | 939050-40-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(2,2-diethoxyethoxy)-3-butoxybenzene
• 英文别名: 1-Butoxy-3-(2,2-diethoxyethoxy)benzene
• CAS: 939050-40-5
• 化学式: C₁₆H₂₆O₄
• 分子量: 282.38
• InChiKey: VXYNFOYNBAXWBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• S1P receptor modulating compounds and use thereof
  申请人：Saha Ashis K.

  公开号：US20080064677A9

  公开（公告）日：2008-03-13

  The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

  本发明涉及一般式（I）的化合物，其作为S1P受体调节剂具有活性，并使用这种化合物来治疗与不适当的S1P受体活性相关的疾病。这些化合物可以用作免疫调节剂，例如，用于治疗或预防自身免疫和相关免疫性疾病，包括全身性红斑狼疮、炎症性肠病（如克罗恩病和溃疡性结肠炎）、1型糖尿病、葡萄膜炎、牛皮癣、重症肌无力、类风湿性关节炎、非肾小球性肾病、肝炎、Behcet病、肾小球肾炎、慢性血小板减少性紫癜、溶血性贫血、肝炎和Wegner肉芽肿；以及用于治疗其他疾病。
• S1P Receptor Modulating Compounds and Use Thereof
  申请人：Saha Ashis K.

  公开号：US20110059945A1

  公开（公告）日：2011-03-10

  The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

  本发明涉及一般式（I）的化合物，其具有作为S1P受体调节剂的活性，以及使用这些化合物治疗与不适当的S1P受体活性相关的疾病。这些化合物可用作免疫调节剂，例如，用于治疗或预防自身免疫和相关免疫性疾病，包括全身性红斑狼疮、克罗恩病和溃疡性结肠炎、I型糖尿病、葡萄膜炎、银屑病、重症肌无力、类风湿性关节炎、非肾小球性肾病、肝炎、Behçet病、肾小球肾炎、慢性血小板减少性紫癜、溶血性贫血、肝炎和Wegner肉芽肿；以及用于治疗其他疾病。
• US7855193B2
  申请人：——

  公开号：US7855193B2

  公开（公告）日：2010-12-21
• US7919519B2
  申请人：——

  公开号：US7919519B2

  公开（公告）日：2011-04-05
• [EN] S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSES MODULATEURS DU RECEPTEUR S1P ET UTILISATION ASSOCIEE
  申请人：PREDIX PHARMACEUTICALS HOLDING

  公开号：WO2007061458A2

  公开（公告）日：2007-05-31

  [EN] The present invention relates to compounds of the general formula (I) that have activity as SlP receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate SlP receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.
  [FR] La présente invention concerne des composés représentés par la formule générale (I) qui présentent une activité en tant qu'agents modulateurs du récepteur S1P, ainsi que l'utilisation desdits composés afin de traiter des maladies associées à une activité du récepteur S1P inappropriée. Lesdits composés peuvent être utilisés en tant qu'immunomodulateurs, par ex., pour traiter ou prévenir des maladies telles que les affections auto-immunes et liées à l'immunité, notamment le lupus érythémateux disséminé, les maladies intestinales inflammatoires telles que la maladie de Crohn et la rectocolite hémorragique, le diabète de type I, l'uvéite, le psoriasis, la myasthénie grave, la polyarthrite rhumatoïde, la néphrite non glomérulaire, l'hépatite, la maladie de Behçet, la glomérulonéphrite, le purpura thrombocytopénique chronique, l'anémie hémolytique, l'hépatite et le granulome de Wegner; et pour traiter d'autres affections.